Pioglitazone Tablets Special Drug Use Surveillance "Combined Use of Insulin Products / Long-term Treatment"

Type 2 Diabetes Mellitus Clinical Trial

Official title:

Actos Tablets Special Drug Use Surveillance "Combined Use of Insulin Products / Long-term Treatment"

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02068508
• Other study ID #: 237-018
• Secondary ID: JapicCTI-132376J
• Status: Completed
• Start date: July 30, 2009
• Est. completion date: June 30, 2014

Study information

• Verified date: February 2019
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to investigate the safety and efficacy of long-term treatment with pioglitazone (Actos Tablets) in the routine clinical setting in combination with an insulin product in patients with type 2 diabetes mellitus who responded inadequately when using an insulin product in addition to diet therapy and exercise therapy.

Description:

This is a special drug use surveillance on long-term use of newly co-administered pioglitazone tablets (Actos Tablets) as part of routine medical care in patients with type 2 diabetes mellitus who have poorly controlled blood glucose when using an insulin product in addition to diet therapy and exercise therapy; this survey is designed to determine the safety and efficacy of long-term use of pioglitazone tablets (Actos Tablets) in the routine clinical setting in combination with an insulin product (the planned sample size, 1000.) The usual adult dosage is 15 mg of pioglitazone administered orally once daily before or after breakfast. Dose adjustment will be made according to gender, age, and symptoms with an upper limit of 30 mg.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1067
• Est. completion date: June 30, 2014
• Est. primary completion date: June 30, 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

Participants with type 2 diabetes mellitus assumed to have insulin resistance who responded inadequately when using an insulin product in addition to diet therapy and exercise therapy who meet the following criteria at enrollment.

1. Participants treated with an insulin product for at least 4 weeks

2. Participants who started Actos Tablets for the first time after the start of an insulin product

3. Participants likely to be available for a 52-week observation and evaluation after the start of co-administration of Actos Tablets

Exclusion Criteria:

Participants with contraindications to Actos Tables and insulin products treatment

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Type 2 Diabetes Mellitus

Intervention

Drug:
• Pioglitazone
Pioglitazone Tablets

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Takeda

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants Who Experience at Least One Adverse Drug Reactions (ADRs)	ADRs are defined as adverse events (AEs) which are in the investigator's opinion of causal relationship to the study treatment. AEs are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product reported from the first dose of study drug to the last dose of study drug.	Up to Week 52
Secondary	Change From Baseline in Fasting Blood Glucose		Baseline and Week 12, 24, 36, 52, and final assessment (up to Week 52)
Secondary	Change From Baseline in Glycosylated Hemoglobin (HbA1c)		Baseline and Week 12, 24, 36, 52, and final assessment (up to Week 52)
Secondary	Change From Baseline in Fasting Triglycerides		Baseline and Week 12, 24, 36, 52, and final assessment (up to Week 52)
Secondary	Change From Baseline in HDL Cholesterol		Baseline and Week 12, 24, 36, 52, and final assessment (up to Week 52)
Secondary	Change From Baseline in LDL Cholesterol		Baseline and Week 12, 24, 36, 52, and final assessment (up to Week 52)
Secondary	Number of Participants Who Received Specific Daily Dose of Insulin Product at Each Time Points	Number of participants who received study drug and specific daily dose of insulin product during the survey was reported. Daily dose of insulin was categorized by < 30 units, >= 30 and < 60 units, >= 60 and < 90 units, >= 90 units at each time points.	Baseline, Week 52, and final assessment (up to Week 52)